Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France Steps Up Scrutiny Of Epilepsy Drug Risks In Pregnancy

Executive Summary

The French health authorities are looking more widely at the actual or potential risks of using anti-epileptic medicines in pregnancy or in women of child bearing age. Valproate is a particular focus, but other drugs like topiramate and pregabalin are also in the frame.
Advertisement

Related Content

EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS125281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel